Skip to content Skip to footer

Manifold Bio Partners with Roche to Develop BBB shuttles for Neurological and Neurodegenerative Diseases

Shots: Manifold has entered into a strategic research collaboration & licensing deal with Roche to develop multiple next-gen blood-brain barrier (BBB) shuttles for neurological & neurodegenerative diseases, leveraging Manifold’s shuttle portfolio & mDesign AI-driven in vivo discovery platform As per the deal, Manifold will lead research & discovery of BBB shuttles for Roche’s therapeutic payloads,…

Read more

Skyhawk Therapeutics Enters a ~$2B Deal with Merck KGaA to Identify RNA-Targeting Small Molecules for Neurological Disorders

Shots: Skyhawk Therapeutics has entered into a strategic research collaboration with Merck KGaA to discover novel RNA-targeting small molecules for neurological diseases with limited treatment options Skyhawk will receive ~$2B incl. upfront, milestones, & potential tiered royalties, leading discovery & preclinical development, while Merck KGaA gains exclusive global rights & handles further development & commercialization upon…

Read more

Exclusive_Jeremiah Robison_2022

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the US FDA’s clearance of Neural Sleeve for patients with cerebral palsy, MS, stroke, and other disorders Cionic’s Neural Sleeve has received the US FDA clearance for functional electrical stimulation to assist in gait for patients with foot drop and leg muscle weakness. The lightweight…

Read more